Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates

Abstract

IMPORTANCE Previous studies have reported that drug treatments, particularly treatment with bisphosphonates, is associated with reduced overall mortality rates in addition to decreased fracture risk. If so, drug treatments should be recommended for this reason alone, regardless of a patient's risk of fracture.OBJECTIVE To assess whether randomized clinical trials demonstrate that treatment with bisphosphonates, particularly zoledronate, is associated with reduced mortality rates.DATA SOURCES Science Direct, MEDLINE, Embase, and the Cochrane Library were searched for randomized placebo-controlled clinical trials of drug treatments for osteoporosis published after 2009 and published or in press before April 19, 2019. Conference abstracts from annual osteoporosis society meetings were also included in the search.STUDY SELECTION Included studies were clinical trials that (1) were randomized and placebo-controlled; (2) studied drug treatments with proven antifracture efficacy; (3) used agents at the approved dose for treatment of osteoporosis; and (4) had a duration of 1 year or more. Abstracts from the literature searches were reviewed for inclusion and exclusion criteria, and mortality rate data were abstracted from the article by 1 researcher and validated by a second. A total of 2045 records were screened; 38 (1.8%) were included in the meta-analyses. DATA EXTRACTION AND SYNTHESISThe Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist was followed for abstracting data and assessing data quality and validity. Data were pooled using random-effects models, and between-study variability was assessed using the I 2 index. The risk of bias for each study was assessed, and funnel plots and Egger and Begg statistics were used to evaluate publication bias. MAIN OUTCOMES AND MEASURESAssociations of all drug treatments, particularly bisphosphonate and zoledronate treatments, with overall mortality. RESULTSOf 38 clinical trials that included 101 642 unique participants, 38 were included in the meta-analyses of all drug treatments (45 594 participants randomized to placebo; 56 048 to treatment); 21 clinical trials, of bisphosphonate treatments (20 244 participants randomized to placebo; 22 623 to treatment); and 6 clinical trials, of zoledronate treatments (6944 participants randomized to placebo; 6926 to treatment). No significant association was found between all drug treatments for osteoporosis and overall mortality rate (risk ratio [RR], 0.98; 95% CI, 0.91-1.05; I 2 = 0%). Clinical trials of bisphosphonate treatment (RR, 0.95; 95% CI, 0.86-1.04) showed no significant association with overall mortality. Also, clinical trials of zoledronate treatment (RR, 0.88; 95% CI, 0.68-1.13) showed no association with overall mortality rate; however, evidence existed for heterogeneity of the results (I 2 = 48.2%). CONCLUSIONS AND RELEVANCEResults of this meta-analysis suggest that bisphosphonate treatment may not be associated with reduced overall mortality rates in addition to decreased fracture risk an...

Corilagin suppresses RANKL‐induced osteoclastogenesis and inhibits oestrogen deficiency‐induced bone loss via the NF‐κB and PI3K/AKT signalling pathways

“…Over‐activated osteoclastogenesis followed by increased levels of inflammatory factors, such as nuclear factor‐κB ligand (RANKL) and tumour necrosis factor‐α (TNF‐α), is the mechanism of osteoporosis development 11‐13 . Mature osteoclasts contain three or more nuclei and are transformed from the monocyte/macrophage lineage upon stimulation by macrophage colony‐stimulating factor (M‐CSF)and RANKL 14 .…”

Quantitative Vertebral Bone Density Seen on Chest CT in Chronic Obstructive Pulmonary Disease Patients: Association with Mortality in the Korean Obstructive Lung Disease Cohort

“…Fourth, information on the use of medication for osteoporosis was not documented in our patients and the possible effects of antiosteoporosis drugs on DThorax and mortality were not investigated. However, a recent meta-analysis reported that osteoporosis treatment was not associated with a reduction in overall mortality (50). Finally, the study population was only Korean.…”

Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs

“…The possible cardioprotective effects of bisphosphonates remain under scrutiny, and there is certainly not sufficiently robust, cohesive data to support a recommendation for this class of medications to be used to treat cardiovascular disease, or even to recommend using them to treat osteoporosis in those at high risk of MI or stroke. A recent meta-analysis reported that mortality was not altered by bisphosphonate treatment [87].…”